Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
View/ Open
Date
2016-08-10Author
Smyth, EC
Fassan, M
Cunningham, D
Allum, WH
Okines, AFC
Lampis, A
Hahne, JC
Rugge, M
Peckitt, C
Nankivell, M
Langley, R
Ghidini, M
Braconi, C
Wotherspoon, A
Grabsch, HI
Valeri, N
Type
Journal Article
Metadata
Show full item recordAbstract
PURPOSE: The Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial established perioperative epirubicin, cisplatin, and fluorouracil chemotherapy as a standard of care for patients with resectable esophagogastric cancer. However, identification of patients at risk for relapse remains challenging. We evaluated whether pathologic response and lymph node status after neoadjuvant chemotherapy are prognostic in patients treated in the MAGIC trial. MATERIALS AND METHODS: Pathologic regression was assessed in resection specimens by two independent pathologists using the Mandard tumor regression grading system (TRG). Differences in overall survival (OS) according to TRG were assessed using the Kaplan-Meier method and compared using the log-rank test. Univariate and multivariate analyses using the Cox proportional hazards method established the relationships among TRG, clinical-pathologic variables, and OS. RESULTS: Three hundred thirty resection specimens were analyzed. In chemotherapy-treated patients with a TRG of 1 or 2, median OS was not reached, whereas for patients with a TRG of 3, 4, or 5, median OS was 20.47 months. On univariate analysis, high TRG and lymph node metastases were negatively related to survival (Mandard TRG 3, 4, or 5: hazard ratio [HR], 1.94; 95% CI, 1.11 to 3.39; P = .0209; lymph node metastases: HR, 3.63; 95% CI, 1.88 to 7.0; P < .001). On multivariate analysis, only lymph node status was independently predictive of OS (HR, 3.36; 95% CI, 1.70 to 6.63; P < .001). CONCLUSION: Lymph node metastases and not pathologic response to chemotherapy was the only independent predictor of survival after chemotherapy plus resection in the MAGIC trial. Prospective evaluation of whether omitting postoperative chemotherapy and/or switching to a noncross-resistant regimen in patients with lymph node-positive disease whose tumor did not respond to preoperative epirubicin, cisplatin, and fluorouracil may be appropriate.
Collections
Subject
Lymph Nodes
Humans
Adenocarcinoma
Esophageal Neoplasms
Stomach Neoplasms
Lymphatic Metastasis
Cisplatin
Fluorouracil
Epirubicin
Proto-Oncogene Proteins B-raf
Receptor, erbB-2
Antineoplastic Combined Chemotherapy Protocols
Chemotherapy, Adjuvant
Neoadjuvant Therapy
Lymph Node Excision
Survival Rate
Aged
Middle Aged
Female
Male
Tumor Suppressor Protein p53
Proto-Oncogene Proteins p21(ras)
PTEN Phosphohydrolase
Phosphatidylinositol 3-Kinases
Class I Phosphatidylinositol 3-Kinases
Research team
Signal Transduction & Molecular Pharmacology
Medicine (RMH Smith Cunningham)
Evolutionary Genomics & Modelling
Gastrointestinal Cancer Biology and Genomics
Language
eng
Date accepted
2016-04-07
License start date
2016-08
Citation
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016, 34 (23), pp. 2721 - 2727
Publisher
AMER SOC CLINICAL ONCOLOGY